Journal of Positive Psychology & Wellbeing
2022, Vol. 6, No. 4, 232 – 235

http://journalppw.com
ISSN 2587-0130

An Overview of Immunoassay Test and Analysis, Roles of General Physicians, Nurses, Medical Coding and Clinical Laboratory Specialists

Hashem Abdulwhab Jaml Allil[1], Abdulaziz Bakheet Bakheet Alharbi[2], Amani Saleh Hussain Alalasy[3], Abdulraheem Mulfi Almutairy[4], Wejdan Mohammed Sahab Al-Harbi[5], Ghadeer Fareeh Alshammari[6], Aisha Abdulaziz Aldiab[6], Majed Saleh Alhafithi[7], Wedad Salem Aljohani[8], Fatimah Zubeer Barnaw[9], WJdaen Bandar Mohsen Alameer[10], Shaza Hussian Alnassri[11], Tammani Halil Alanzi[12], Amani Mohammad Alshehri[12], Sabah Auda Alsaid[13]

[1]*King abdulaziz hospital makkah, General practice*
[2]*Male laboratory technician, Mecca Complex - Ibn Sina Hospital - Medical Services - Technicians*
[3]*Specialist Nursing, King salman bin abdulaziz medical city.*
[4]*Specialist Nursing, Eradh Complex for Mental Health*
[5]*Al-Matar Primary Health Care Centre, Nursing technician*
[6]*Nursing technician, Dammam Medical Complex*
[7]*Alyis general hospital, nursing specialist*
[8]*Alyis general hospital, technician-nursing*
[9]*Nursing specialist, Ajyad Emergency Hospital*
[10]*Hira General Hospital, Medical coding technician*
[11]*Medical Coding Technician, Hera'a General Hospital*
[12]*Nursing specialist, Al Murabba Health Center*
[13]*Nursing, Dowaima health care*

Abstract

The standards that must be met in order to fulfill the requirements of laboratory consulting services, which include the discussion of particular clinical cases. A presentation is made regarding the information that pertains to the grounds of interpretation of the results of laboratory analyses. The methods of comparison with reference intervals, values, and decision thresholds, as well as the evaluation of the effects of various types of non-pathogenic variations, including pharmaceuticals taken by the patient, are taken into consideration. This requires the collaboration of general physicians, nurses, medical coding specialists, and clinical laboratory specialists. The necessity of taking an individual approach in clinical decision making is highlighted, as is the fact that traditional evaluation of produced outcomes is not acceptable. Particular focus is placed on the obligation of the laboratory to promptly alert doctors about any observed important abnormalities in laboratory indicators in patients who are at a high risk of experiencing an undesirable result.

Keywords*: consulting services, laboratory analyses, clinical decision.*

Introduction

Immunoassays are bioanalytical techniques that rely on the interaction between an antigen (analyte) and an antibody to measure the amount of the analyte. These methods primarily rely on a competitive binding reaction between a predetermined quantity of a labeled form of the substance being analyzed and a varying

quantity of the unlabeled sample substance for a restricted number of binding sites on a highly specific antibody that targets the substance being analyzed. When these immunoanalytical reagents are combined and allowed to undergo incubation, the analyte becomes attached to the antibody, resulting in the formation of an immunological complex. The complex is isolated from the unbound reagent fraction using either a physical or chemical separation approach. Analysis is accomplished by quantifying the level of label activity (such as radiation, fluorescence, or enzyme) in either the bound or unbound fraction. A standard curve is built to depict the relationship between the observed signal and the concentration of the unlabelled analyte in the sample. The concentration of an unknown analyte is measured using this calibration curve [1].

Immunoassay techniques have been extensively utilized in various crucial domains of pharmaceutical analysis, including illness diagnosis, monitoring of therapeutic drugs, clinical pharmacokinetics, and bioequivalence investigations in drug discovery and the pharmaceutical industry. The study in these domains typically entails quantifying extremely low concentrations of low molecular weight medicines, macromolecular macromolecules with pharmacological relevance, metabolites, and/or biomarkers that signal disease diagnosis or prognosis [2]. The significance and extensive use of immunoassay techniques in pharmaceutical analysis can be due to its inherent specificity, ability to process large volumes of samples, and high sensitivity in detecting a wide range of substances in biological samples. The detection mechanism in immunoassays relies on easily detectable markers (such as radioisotopes or enzymes) attached to one of the immunoanalytical substances (either the analyte or the antibody). Utilizing these labels in immunoassays leads to assay methods that exhibit exceptional sensitivity and minimal detection limits [3]. When it is necessary to determine the precise quantities of big molecules at the femtomole to attomole level in complicated biological samples, immunoassays are undoubtedly the preferred methods due to their exceptional specificity and sensitivity [4].

During the initial phases of drug discovery and development, namely in the clinical pharmacokinetic investigations of a novel drug candidate, it is necessary to screen a substantial number of samples. Only a high-throughput analytical approach can accomplish this. Immunoassay methods can be used to analyze complex biological matrices, such as blood or urine, without the need for sample pretreatment. These methods rely on particular binding reactions. [5] While the development of a new immunoassay method for an analyte may be time-consuming, typically taking months to generate the desired antibody, once appropriate immunoanalytical reagents are obtained, the establishment of the immunoassay method can be done within a timeframe that is comparable to chromatographic methods. In addition, innovative methods were devised to facilitate the fast synthesis of targeted antibodies. These techniques led to a significant reduction in the time needed to develop immunoassay methods [6].

The function of the clinical microbiology laboratory is swiftly developing as the provision of healthcare undergoes significant transformations. Laboratories are no longer generating revenue. Currently, they are seen as departments that incur expenses and must prove their worth by showing enhanced quality and safety to enhance patient care. Laboratories have transitioned from being isolated repositories of information to being seamlessly integrated into the quality framework in order to deliver services that prioritize the needs of patients. In light of this development, laboratory personnel need to be familiarized with the integration of their processes and procedures with their organization's quality management system (QMS) [7].

Review:

Pharmaceutical analysis utilizes immunoassay methods, which can be categorized as either heterogeneous or homogeneous assays, depending on whether a separation step is necessary. These strategies can be executed in either competitive or non-competitive formats. The selection of these designs depends on the nature of the analyte, the available labeling chemistry, and the desired analytical parameter of the assay (such as sensitivity, dynamic range, and precision). Immunoassays can be competitively designed in either an antigen-capture or antibody-capture configuration,

depending on whether the solid phase is coated with antibody or antigen (analyte), respectively. In the antigen-capture format, the competition reaction takes place between the analyte (present in the sample) and a labeled analyte, both vying for binding to a restricted quantity of anti-analyte antibody that is coated onto a solid substrate. Following the process of equilibration and separation, the level of labeling activity on the solid phase is determined. This observed signal is inversely related to the concentrations of the analyte present in the sample [8]. The analyte (or its protein conjugate) is immobilized onto a solid substrate using the antibody-capture format. The competition takes place between the analyte present in the sample and the immobilized analyte, as they both vie for binding to a restricted quantity of labeled anti-analyte antibody. Following the process of equilibration and separation, the level of label attached to the solid support is determined, and the signal obtained is inversely proportional to the concentration of the substance being analyzed. The non-competitive design, sometimes referred to as the "two-site" or "sandwich" assay, is employed for big analytes that have multiple recognition epitopes on their molecule. Two antibodies are needed that attach to different parts of the analyte molecules and do not overlap with each other [8].

The reagents consist of antibodies, signal-generating labels, and separation matrices. Antibodies are crucial substances that determine the success of any immunoassay. Antibodies can exist in two forms: polyclonal or monoclonal. Monoclonal antibodies are more favorable than polyclonal antibodies for the production of immunoassays in pharmaceutical analysis. This can be ascribed to their greater affinity and specificity for the analyte. Despite this, numerous effective immunoassays have been created employing polyclonal antibodies due to their ability to manufacture antibodies with a strong affinity for the analyte [9].

The labels used for generating signals in immunoassays consist primarily of radioactive atoms, such as 125I, 3H, and 14C. Radioactive labels provide highly sensitive and accurate assays, but they come with certain disadvantages such as health risks, the need for careful handling of reagents, staff training requirements, the short half-life of the isotope, and the need for expensive equipment to measure radioactivity. Consequently, alternative non-radioactive markers such as enzymes, fluorescent probes, chemiluminescent compounds, metals and metal chelates, and liposomes were introduced. Enzymes are the most often used labels in immunoassay methods for pharmaceutical substances, based on the number of publications. An advantage of using enzyme labels in immunoassays is the potential for signal amplification, which can increase the sensitivity of the procedure. This is advantageous when the initial signal is insufficient to provide the desired level of sensitivity for the analysis[10].

The matrices employed for the isolation of immune complexes resulting from immunoanalytical reactions encompass charcoal, polyethylene glycol, secondary antibody, microbeads, or the highly advantageous 96-well microwell plates. Each well of the plate functions as an individual reaction tube. The reaction involves coating one component (either the analyte or antibody) onto the bottom surface of the plate wells, resulting in the formation of the immunological complex on the well surface. These plates aid in the washing processes and pipetting of reagents, resulting in a partial automation of the method [11].

Conclusion:

The field of diagnostic technology is advancing quickly, and significant advancements have been made in the past ten years, particularly in the identification of antibodies. These advancements are bringing this form of diagnostic closer to the level of automated clinical chemistry laboratories. This technology is highly advanced in the clinical laboratory due to its wide dynamic range, which exceeds that of immunoenzymatic methods. It also offers high sensitivity and specificity, with results expressed in quantitative form. Additionally, it has a high degree of automation and allows for running a large number of antibody tests directed towards large antigenic panels in random access mode. These features have significant implications for the reduction in turnaround time and greatly impact the workflow and organization of autoimmunology laboratories. Anticipated advancements in the

near future include the creation of new analytical platforms like the flow-injection chemiluminescent immunoassay, the two-dimensional resolution for chemiluminescence multiplex immunoassay, and the magnetic nanoparticles chemiluminescence immunoassay. These developments are expected to further enhance the effectiveness of antibody tests in clinical settings. The immunoassay test and analysis heavily rely on the vital contributions of physicians, nurses, and medical coding.

Reference

[1] Mohit E., Rostami Z., Vahidi H. A comparative review of immunoassays for COVID-19 detection. Expert Rev. Clin. Immunol. 2021;17:573–599. doi: 10.1080/1744666X.2021.1908886.

[2] Di Nardo F., Chiarello M., Cavalera S., Baggiani C., Anfossi L. Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives. Sensors. 2021;21:5185. doi: 10.3390/s21155185.

[3] Andryukov B.G. Six decades of lateral flow immunoassay: From determining metabolic markers to diagnosing COVID-19. AIMS Microbiol. 2020;6:280–304. doi: 10.3934/microbiol.2020018.

[4] Shirshahi V., Tabatabaei S.N., Hatamie S., Saber R. Photothermal enhancement in sensitivity of lateral flow assays for detection of E-coli O157:H7. Colloids Surf. B Biointerfaces. 2020;186:110721. doi: 10.1016/j.colsurfb.2019.110721.

[5] Guo J., Chen S., Guo J., Ma X. Nanomaterial Labels in Lateral Flow Immunoassays for Point-of-Care-Testing. J. Mater. Sci. Technol. 2021;60:90–104. doi: 10.1016/j.jmst.2020.06.003.

[6] Urusov A.E., Zherdev A.V., Dzantiev B.B. Towards Lateral Flow Quantitative Assays: Detection Approaches. Biosensors. 2019;9:89. doi: 10.3390/bios9030089.

[7] Ye H., Xia X. Enhancing the sensitivity of colorimetric lateral flow assay (CLFA) through signal amplification techniques. J. Mater. Chem. B. 2018;6:7102–7111. doi: 10.1039/C8TB01603H.

[8] Xiao R., Lu L., Rong Z., Wang C., Peng Y., Wang F., Wang J., Sun M., Dong J., Wang D., et al. Portable and multiplexed lateral flow immunoassay reader based on SERS for highly sensitive point-of-care testing. Biosens. Bioelectron. 2020;168:112524. doi: 10.1016/j.bios.2020.112524.

[9] Park J. An Optimized Colorimetric Readout Method for Lateral Flow Immunoassays. Sensors. 2018;18:4084. doi: 10.3390/s18124084.

[10] Zeng N., You Y., Xie L., Zhang H., Ye L., Hong W., Li Y. A new imaged-based quantitative reader for the gold immunochromatographic assay. Optik. 2018;152:92–99. doi: 10.1016/j.ijleo.2017.09.109.

[11] Saisin L., Amarit R., Somboonkaew A., Gajanandana O., Himananto O., Sutapun B. Significant Sensitivity Improvement for Camera-Based Lateral Flow Immunoassay Readers. Sensors. 2018;18:4026. doi: 10.3390/s18114026.